Rybrevant for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinumbased chemotherapy as of December 2022 MARA Rating Company February 10, 2026 Read More »
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis as of August 2025 MARA Rating Company December 16, 2025 Read More »
Neupogen / filgrastim for the treatment of severe chronic neutropenia as of August 2025 MARA Rating Company December 16, 2025 Read More »
Bivigam for primary humoral immunodeficiency as of August 2025 MARA Rating Company December 16, 2025 Read More »
Ohtuvayre / ensifentrine for maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) as of July 2025 MARA Rating Company December 16, 2025 Read More »
Deucrictibant for on-Demand Treatment of HAE Attacks as of September 2025 MARA Rating Company December 16, 2025 Read More »
Baxdrostat for treating uncontrolled and resistant hypertension as of September 2025 MARA Rating Company December 16, 2025 Read More »
Nipocalimab for generalized myasthenia gravis as of August 2025 MARA Rating Company December 16, 2025 Read More »
Suzetrigine for treating neuropathic pain as of August 2025 MARA Rating Company December 16, 2025 Read More »
Mavorixafor for severe chronic neutropenia as of August 2025 MARA Rating Company December 16, 2025 Read More »